Baker Brothers Life Sciences Files Intent to Sell $2.65M in Protara Therapeutics Stock
Summary
Baker Brothers Life Sciences, a former affiliate, filed a Form 144 to sell 424,125 shares of Protara Therapeutics common stock, valued at $2.65 million, continuing a recent pattern of significant share dispositions.
Key Events
-
Intent to Sell Significant Stake
Baker Brothers Life Sciences, L.P. filed a Form 144 indicating intent to sell 424,125 shares of Protara Therapeutics common stock, with an approximate market value of $2,654,641.00.
-
Continuation of Selling Pattern
This filing is part of a series of Form 144s from Baker Brothers and its affiliates, including 667, L.P., which collectively indicate an ongoing reduction of their holdings in Protara Therapeutics, following previous filings on February 25 and 26.
-
Former Affiliate Status
The filer, Baker Brothers Life Sciences, L.P., is identified as a 'Former Affiliate' of Protara Therapeutics, Inc.
Analysis
This Form 144 indicates Baker Brothers Life Sciences, a significant institutional investor and former affiliate, intends to sell an additional 424,125 shares of Protara Therapeutics common stock, valued at approximately $2.65 million. This filing follows a series of similar Form 144s from Baker Brothers and its affiliates in late February, signaling a continued reduction of their stake in the company. While the company recently reported positive interim Phase 2 trial results, this ongoing selling pressure from a major investor could create an overhang on the stock.
At the time of this filing, TARA was trading at $6.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $320.1M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.